Colchicine
What studies of colchicine found
At a glance, by condition
Long COVID: B May help
Based on the strongest evidence, the randomised trial (low certainty): 2 findings, all B.
3 outcomes rated · see each below
Both together: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for overall symptoms.
3 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, colchicine may help, but the evidence is still limited. For long COVID and ME/CFS studied together, colchicine might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- Colchicine · Long COVID is hereBMay helpImprovement, low certainty
- Colchicine · Both together is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Fatigue1 study · 160 people took colchicine Improvement B
Why this grade: Improvement, low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight.
The randomised trial778 randomised · 668 analysed · 12 weeks (primary endpoint); 24 weeks (secondary endpoint, 12 weeks after drug cessation) · 500 μg, twice daily
Fatigue improved more than in the comparison group.
Colchicine may reduce fatigue in long COVID. Improvement · low certainty B
- High risk of bias (RoB 2) in the results that carry most of the weight
See the 1 study
-
- People in the study
- 778 randomised · 668 analysed
- Dose
- 500 μg, twice daily
- Outcome
- 12-week FAS score Fatigue Assessment Scale
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- High
Anxiety1 study · 162 people took colchicine Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (346 in all).
The placebo trial350 randomised · 346 analysed · 26 weeks · 0.5 mg, once daily for individuals with body weight of 70 kg or less or colchicine, 0.5 mg, twice daily if body weight was greater than 70 kg
Anxiety improved more than in the comparison group.
The evidence is very uncertain about the effect of colchicine on anxiety in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (346 in all)
See the 1 study
-
Effectiveness of Colchicine for the Treatment of Long COVID: A Randomized Clinical Trial. (2025)
- People in the study
- 350 randomised · 346 analysed
- Dose
- 0.5 mg, once daily for individuals with body weight of 70 kg or less or colchicine, 0.5 mg, twice daily if body weight was greater than 70 kg
- Outcome
- GAD-7 score at 52 wk (adjusted mITT analysis) Generalized Anxiety Disorder-7
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Daily life and health overall
Quality of life1 study · 160 people took colchicine Improvement B
Why this grade: Improvement, low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight.
The randomised trial778 randomised · 668 analysed · 12 weeks (primary endpoint); 24 weeks (secondary endpoint, 12 weeks after drug cessation) · 500 μg, twice daily
Quality of life improved more than in the comparison group.
Colchicine may improve quality of life in long COVID. Improvement · low certainty B
- High risk of bias (RoB 2) in the results that carry most of the weight
See the 1 study
-
- People in the study
- 778 randomised · 668 analysed
- Dose
- 500 μg, twice daily
- Outcome
- EQ-VAS score at 12 weeks EQ-5D-5L visual analogue scale
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Both together
Symptoms
Cognition (brain fog)1 study · 1 (few people) person took colchicine Uncertain –
Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.
Studies with no comparison group1 in the study · after four weeks · 0.5 mg a day (few people)
Too little to say about cognition (brain fog).
Too little to say: cognition (brain fog) got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
- One study saw it get worse, without a test against chance
See the 1 study
-
WORSENING OF LETHARGY POST SARS‐COV‐2 VACCINATION IN A PATIENT WITH ME/CFS (2022)
- People in the study
- 1 in the study
- Dose
- 0.5 mg a day
- Outcome
- cognitive skills
- Effect
- worse (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took colchicine Uncertain –
Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.
Studies with no comparison group1 in the study · after four weeks · 0.5 mg a day (few people)
Too little to say about fatigue.
Too little to say: fatigue got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
- One study saw it get worse, without a test against chance
See the 1 study
-
WORSENING OF LETHARGY POST SARS‐COV‐2 VACCINATION IN A PATIENT WITH ME/CFS (2022)
- People in the study
- 1 in the study
- Dose
- 0.5 mg a day
- Outcome
- lethargy
- Effect
- worse (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Overall symptoms1 study · 1 (few people) person took colchicine Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · after four weeks · 0.5 mg a day (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of colchicine on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
WORSENING OF LETHARGY POST SARS‐COV‐2 VACCINATION IN A PATIENT WITH ME/CFS (2022)
- People in the study
- 1 in the study
- Dose
- 0.5 mg a day
- Outcome
- level of energy and cognitive skills
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Studies of combinations
Outcomes that only studies of colchicine given together with other treatments looked at. Shown, not graded: they can’t tell what colchicine did alone.
Low mood or anxiety ME/CFS
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): SF-36 – Mental health, better.
Shown, not counted: colchicine was given together with other treatments.
Daily functioning ME/CFS
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): SF-36 – Role limitations due to emotional problems, better.
Shown, not counted: colchicine was given together with other treatments.
Autonomic symptoms ME/CFS
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): Dizziness level, no clear difference.
Shown, not counted: colchicine was given together with other treatments.
Breathlessness ME/CFS
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): Dyspnoea/shortness of breath level, no clear difference.
Shown, not counted: colchicine was given together with other treatments.
Fatigue ME/CFS
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): Fatigue level, no clear difference.
Shown, not counted: colchicine was given together with other treatments.
Side effects
Stopping because of side effects1 study
Discontinuation of trial medication due to AEs occurred in 3 participants in the colchicine group (3 events [1.7%]) and 1 participant in the placebo group (1 event [0.6%]
Effectiveness of Colchicine for the Treatment of Long COVID: A Randomized Clinical Trial. (2025)
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Nausea or stomach upset | 2 studies |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
0.5 mg at the start in most studies
- 2Raise
Raised step by step in 1 of 4 studies
- 3Top dose
Most often 0.5 mg (3 of 4 studies)
Doses across 4 studies
0.5 to 0.5 mg. One study of 547 people went up to 5 mg.
Each study’s dose, as printed
- 0.5 mg, once daily for individuals with body weight of 70 kg or less or colchicine, 0.5 mg, twice daily if body weight was greater than 70 kg Effectiveness of Colchicine for the Treatment of Long COVID: A Randomized Clinical Trial. (2025)
- 0.5 mg/day White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024)
- 0.5 mg a day WORSENING OF LETHARGY POST SARS‐COV‐2 VACCINATION IN A PATIENT WITH ME/CFS (2022)
- up to a 5 mg loading dose High Colchicine Doses Are More Effective in COVID-19 Outpatients than Nirmatrelvir/Ritonavir, Remdesivir, and Molnupiravir (2024)
All papers
- Effectiveness of Colchicine for the Treatment of Long COVID: A Randomized Clinical Trial.2025 · placebo trial · 350 randomised · 346 analysed
Summary
This double-blind, 1:1 randomized clinical trial asked whether colchicine improves outcomes in adults with long COVID. Participants were recruited from 8 sites across 6 states in India. A total of 350 participants were randomized: 177 to colchicine and 173 to placebo. The modified intention-to-treat analysis included 346 participants (162 colchicine, 157 placebo). Colchicine was given as 0.5 mg once or twice daily based on body weight, or matching placebo, for 26 weeks; outcomes were assessed at 12, 26, and 52 weeks. The primary outcome was change in 6-minute walk test distance from baseline to 52 weeks. At 52 weeks, the mean change was 35.55 m with colchicine and 29.96 m with placebo (mean difference, 5.59 m; 95% CI, –9.00 to 20.18; P = .45), with no statistically significant difference between groups. The paper reports no statistically significant differences across secondary outcomes except the FEV1/FVC ratio at 52 weeks (mean difference, 0.04; 95% CI, 0.02 to 0.07; P = .001), described as a small, nonclinically relevant difference. Adverse events were reported by 35 participants (19.9%) in the colchicine group (87 AEs) and 30 participants (17.6%) in the placebo group (91 AEs). Discontinuation due to AEs occurred in 3 colchicine participants and 1 placebo participant; 2 deaths occurred in the colchicine group.
- Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial.2026 · randomised trial · 778 randomised · 668 analysed
Summary
This multisite, open-label, randomised controlled trial asked whether repurposed drugs reduce fatigue in adults with long COVID who had not been hospitalised with COVID-19. It took place across 12 UK NHS specialist long COVID care clinics. 778 participants were randomly assigned 1:1:1:1 to colchicine 500 μg twice daily (n=192), famotidine 40 mg with loratadine 10 mg once daily (n=193), rivaroxaban 10 mg once daily (n=197), or no drug (n=196) for 12 weeks; all received usual care. The primary measure was the Fatigue Assessment Scale (FAS, 10 to 50, higher worse) at 12 weeks, with a 24-week FAS secondary endpoint. 668 participants had a calculable 12-week FAS score (160 colchicine, 174 famotidine–loratadine, 171 rivaroxaban, 163 no drug). Mean FAS fell within every group: 4.4 points with colchicine, 4.8 with famotidine–loratadine, 4.4 with rivaroxaban, and 3.3 with no drug. Adjusted differences versus no drug were –1.49 points (95% CI –2.92 to –0.06; p=0.041) for colchicine, –1.48 (–2.88 to –0.08; p=0.038) for famotidine–loratadine, and –1.06 (–2.47 to 0.35; p=0.139) for rivaroxaban. At 24 weeks, differences were –0.043 (p=0.96), 0.34 (p=0.66), and 0.04 (p=0.96). EQ-VAS at 12 weeks was higher by 4.13, 4.84, and 3.5 points in the colchicine, famotidine–loratadine, and rivaroxaban groups. Adverse events were reported by 57 of 192, 51 of 193, 70 of 197, and 21 of 196 participants; ten serious adverse events occurred in eight participants, five in three rivaroxaban participants. The authors state limitations including inability to exclude placebo effects or expectation bias in the open-label trial.
- High Colchicine Doses Are More Effective in COVID-19 Outpatients than Nirmatrelvir/Ritonavir, Remdesivir, and Molnupiravir2024 · compared with another group · 547 in the study
Summary
This questionnaire study collected 547 responses from COVID-19 outpatients in Bulgaria during October 2020 to May 2021. Of these, 496 reported colchicine intake (up to a 5 mg loading dose; mean duration of prophylactic colchicine intake was 46 days) and 51 reported no colchicine. The paper compared hospitalization, post-COVID-19 symptoms, reinfection and diarrhea. Hospitalization after consultation was 6.05% with any colchicine and 25.5% with no colchicine (difference 19.45%, P < 0.0001). The report gives a relative risk reduction of 76.38% and an absolute risk reduction of 20.86%; the discussion states an 87% reduction. Post-COVID-19 symptoms per patient fell by 2.052 (p < 0.001). Reinfection showed no mean difference; total colchicine 25.05% versus no colchicine 34.09% (P = 0.1901). Among 496 colchicine users, 426 confirmed diarrhea related to colchicine use (86.06%), with n = 50 (10%) missing data; light diarrhea was reported in 242, moderate in 123 and severe in 11. No patients died. The authors state that outpatients’ high-dose colchicine treatment practically prevents hospitalizations.
- Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.2024 · no comparison group · 852 in the study · 536 with outcome data
Summary
This cross-sectional follow-up survey asked patients with long COVID seen at a post-COVID clinic (PCoCC) about symptoms and treatments. A total of 852 patients were identified; 536 completed the survey. The mean time from COVID-19 infection to survey completion was 23.2 ± 6.4 months. There was no comparison group; patients rated symptoms at the initial clinic visit (baseline, by recall) and at follow-up on a 1-10 scale, and rated whether treatments were helpful. Surveyed treatments included low-dose naltrexone, vagal nerve stimulator, midodrine, fludrocortisone, pyridostigmine, aripiprazole, plasmapheresis, reishi mushroom and nattokinase/serrapeptase; treatment duration was not reported. Overall functioning median improved from 8 (6, 9) at baseline to 5 (3, 8) at follow-up (P < .001); fatigue improved from 8 (7,10) to 6 (3, 8) and brain fog from 8 (6, 9) to 5 (3, 8) (P < .001 for both). All individual symptoms assessed were significantly improved (P < .001). Only 4.5% (24/536) had recovered completely. Helpful ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulator 18/34 (53%), plasmapheresis 9/9 (100%), midodrine 7/17 (41%), fludrocortisone 8/17 (47%), pyridostigmine 2/3 (67%), aripiprazole 8/17 (47%), reishi mushroom 8/19 (42%) and nattokinase/serrapeptase 5/9 (56%). A minority worsened in overall function and in fatigue, myalgia and orthostasis; counts, side-effect counts, and withdrawals due to harms were not reported.
- Improvement of clinical symptoms and cardiac abnormalities detected by cardiac magnetic resonance imaging in patients with long COVID syndrome after guideline-oriented therapy2023 · no comparison group · 240 in the study · 67 with outcome data · preprint
Summary
This prospective registry cohort (Vienna PostCoV Registry, March 2021 to March 2023) included 240 patients with cardiovascular long COVID syndrome and cardiac magnetic resonance (CMR) scans; patients were 43±13 years old and 67.5% female. CMR abnormalities were found in 126 patients (52.5%). Patients with CMR abnormalities and cardiac symptoms received guideline-oriented medical therapy: low or moderate doses of NSAIDs for 3 months for serositis, blood pressure and condition-adapted heart failure treatment if left and/or right ventricular function was reduced or ventricles were enlarged, or both for myopericarditis; H2-receptor blocker antagonists were added if necessary. Clinical assessment and CMR were repeated in 67 patients with pathological CMR findings 129±51 days after treatment start. Clinical symptoms improved markedly, with a decrease in CMR abnormalities. In patients in the serositis and myopericarditis groups, pericardial effusion decreased from 4.9±3.5 mm to 2.1±2.5 mm (P<0.001, n=41). In patients with ventricular functional impairment with/without pericardial fluidum, LVEF increased from 53.9±7.1% to 57.7±5.4% (P=0.009, n=41). Cumulative CMR abnormalities decreased from 67 (100%) to 42 (62.7%) (P<0.001). Table 1b also reports pericardial effusion 41 (60.3%) to 27 (39.7%) (P=0.024), reduced LVF 26 (38.8%) to 8 (11.9%) (P<0.001), and reduced RVF 18 (26.9%) to 6 (9.0%) (P=0.017). Pleural effusion was 4 (6.0%) at baseline and 6 (9.0%) at follow-up (no P value reported). Harms and withdrawals were not reported.
- Favorable responses to upadacitinib, a JAK1 inhibitor, in long COVID patients with predominant neuropsychiatric symptoms: case reports in 2 autistic patients and one typically developing patient.2025 · case report · 3 in the study
Summary
This paper reports case reports of 3 patients with long COVID and predominant neuropsychiatric symptoms, 2 with autism spectrum disorder (ASD) and one without ASD, seen in the Pediatric Allergy/Immunology Clinic and the authors' clinic. Upadacitinib, a JAK1 inhibitor, was added to treatment that included colchicine; doses recorded were 15 mg once daily, 30 mg once daily, and 15 mg/day increased to 30 mg/day. Treatment duration was not reported. There was no comparison group; changes were assessed before and after upadacitinib. The Aberrant Behavior Check list (ABC) was used in all 3 cases. The authors report noticeable improvement in all ABC subscale scores in the 3 cases; improvement in irritability, lethargy, and hyperactivity within 1–2 weeks in all three cases; and improvement in Case 3 stereotypy. Case 2 appeared to regain some cognitive functioning six months after starting upadacitinib, and speech improved. Case 3 tic symptoms gradually subsided over 4–5 months. Monocyte cytokine data were available for cases 1 and 3. One tonic-clonic seizure occurred in Case 1 when the lamotrigine dose was lowered. The authors state difficulty diagnosing long COVID in ASD cases.
- WORSENING OF LETHARGY POST SARS‐COV‐2 VACCINATION IN A PATIENT WITH ME/CFS2022 · case report · 1 in the study
Summary
This conference abstract reports one case: a 46-year-old male with ME/CFS since 2016, followed at the Noosa Hospital clinic, whose general condition deteriorated after the second dose of SARS-CoV-2 (Pfizer–BioNTech COVID-19) vaccination in August 2021. During September—October 2021 his cognitive skills declined and he had to stop his university studies; the paper also records that he stopped driving his car and could not do any sport recreational activity, and lethargy is named in the title and text. Before vaccination he was on multivitamins, low dose Naltrexone and Spironolactone. In November 2021 Colchicine 0.5 mg a day was started. There was no comparison group. The reported measure was level of energy and cognitive skills. After four weeks of Colchicine plus his previous medication, his level of energy and cognitive skills recovered to pre vaccination status. The abstract does not report colchicine side effects or withdrawals; the recorded harms are the post-vaccination deterioration, cognitive decline, and stopping driving and sport recreational activity, with lethargy reported. The text does not state limitations.
- Endothelial Dysfunction in a Patient With Post-COVID-19 Syndrome and Mutation of the MTHFR Gene and Prothrombin II.2025 · combination: given with other treatments · 1 in the study
Summary
This case report describes a 25-year-old Mexican woman with post-COVID-19 syndrome and chest pain and dyspnea. The report is a single case presentation. One patient was enrolled, started treatment, and was analysed. No comparison group, randomisation, or crossover was reported. Treatment included short-term prophylactic apixaban with low-dose aspirin; colchicine and indomethacin were also initiated; the final treatment consisted of folic acid and vitamin B complex supplementation, low-dose aspirin, bisoprolol, and trimetazidine for angina control. Isosorbide was discontinued due to severe headache, and diltiazem yielded no significant improvement. Treatment duration was not reported; follow-up was at one year. The recorded outcomes were clinical improvement with a reduction in the frequency and intensity of angina, and a significant reduction in frequency and intensity of chest pain. The authors state that at a one-year follow-up the patient showed clinical improvement. Apixaban was discontinued after discharge. The authors acknowledge the limitation of reporting a single case.
- White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome2024 · combination: given with other treatments
Summary
Why: the authors investigated neuroimaging and clinical changes linked with a synergistic off-label treatment (SOT) for ME/CFS. Who: 8 treated ME/CFS patients (SOT) and 8 age-gender matched treatment-naïve ME/CFS patients (control); SOT patients were treated by Dr. do Campo in routine practice, controls randomly selected from an ongoing neuroimaging study. Treatment: oral spironolactone 25 mg/day, colchicine 0.5 mg/day, low dose naltrexone 1.5–4.5 mg/day, and multivitamins for more than 6 months; mean time on protocol 27.75 (10.82) months. Measured: HADS, SF-36, CCC-JDC, standing-task items, and diffusion-weighted imaging. Findings: SOT showed lower HADS depression (8.83 (3.37) vs 13.5 (3.67), p = 0.04*) and higher SF-36 Mental Health (69.33 (13.78) vs 43.2 (15.85), p = 0.01*), plus higher SF-36 Role limitations due to emotional problems (77.78 (27.22) vs 27.78 (44.31), p = 0.04*) and Mental component summary (46.49 (5.38) vs 38.02 (8.89), p = 0.02*). CCC-JDC fell from baseline 20.25 ± 2.92 to post-treatment 10.86 ± 4.49 (PBonf < .001). DWI showed higher FA and lower diffusivity in SOT (PFWE ≤ .05). No significant differences were reported for HADS anxiety (p = 0.23), SF-36 Physical component summary (p = 0.73), or Fatigue level (p = 0.2). Two selected participants were excluded; one was 68 years old and another had to stop spironolactone after developing POTS.
- Colchicine-The Divine Medicine against COVID-19.2024 · review
Summary
This is an opinion-style review by a Bulgarian research group about using colchicine, an old anti-inflammatory drug, to treat acute COVID-19. The author explains why he thinks colchicine should work against the strong inflammation of severe COVID-19, and argues that the usual low doses tested in large trials were too small. Most of the paper is about people in hospital with COVID-19: the author describes several dosing schedules used in four hospitals and his group's earlier reports of lower death rates at higher doses. The paper says that the World Health Organization recommends against colchicine for COVID-19 after large trials found no benefit. The only point about long COVID is a single sentence: the group's own data, which include many outpatients, are said to show that post-COVID symptoms were significantly rarer in people treated with colchicine during their COVID-19 illness. These results are not given in numbers, are not compared with a stated group, and the paper says they have only been presented at conferences and are still being processed for publication. No side effects from this group's own patients are reported in the paper; the author argues that his doses stay below the amounts linked to deaths in poisoning reports.